Board of Directors
Raymond W. Cohen joined Lombard Medical on July 9, 2013 as Non-Executive Chairman. Mr. Cohen has extensive international life science experience having held several Chairman and CEO positions on the boards of both publicly listed and private life sciences companies in the US and Europe. Mr. Cohen currently serves as the Chief Executive Officer and member of the board of directors of Irvine, CA based Axonics Modulation Technologies, Inc., a venture backed developer of neuromodulation devices. Mr. Cohen also currently serves as the Non-executive Chairman of of BioLife Solutions, Inc. (NASDAQ:BLFS), a manufacturer and marketer of biopreservation media for human cells; Nonexecutive Chairman of Syncroness, Inc., a contract engineering firm; Director and Chairman of the Compensation Committee of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a developer and marketer of oncology and haematology drugs; as a Director and member of the Audit and Compensation Committees of LifeWatch AG, (LIFE.SW), a Zurich-based provider of ambulatory ECG services; and as a Director and Chairman of the Audit Committee of Jenavalve Technology, Inc., a venture-backed Irvine, CA based developer, manufacturer of transcatheter aortic valve systems. From mid 2010 to late 2012, Mr. Cohen served as Chief Executive Officer of Vessix Vascular, Inc., a developer of a novel renal denervation system used to treat uncontrolled hypertension. In November 2012, during his tenure as CEO, Vessix was acquired by Boston Scientific Corporation (NYSE:BSX).
John Rush joined Lombard Medical as CEO in 2009, was appointed Non-Executive Chairman in 2011, before stepping down as Non-Executive Chairman in April 2013. Before joining Lombard Mr Rush was President and CEO of North American Scientific, Inc. (NASDAQ: NASM). He re-organized the Company and led an investor group initiative to take the Company private. The new organization is focused on commercializing temporary implants for local radiation delivery. Mr Rush was also President and CEO of MicroTherapuetics, Inc (NASDAQ:MTIX), an interventional neuroradiology company with operations in US and Europe. He orchestrated a successful sale of the company to ev3. Prior to MTIX, Mr Rush spent 10 years with Scimed Life Systems/Boston Scientific in various management roles, including General Manager of Boston Scientific’s Asia Pacific business based in Singapore. Mr Rush has extensive domestic and international experience, with a core sales and marketing background.
Michael H. Carrel joined the Board on February 11, 2015. Mr. Carrel brings more than two decades of leadership experience and presently serves as the President and Chief Executive Officer of ArtiCure, Inc., (NASDAQ: ATRC), a leading medical device company focused on surgical treatments for atrial fibrillation and left atrial appendage management. Since joining AtriCure in November 2012, Mr. Carrel has led the company through significant revenue growth. Prior to joining AtriCure, Mr. Carrel was the President and Chief Executive Officer of Vital Images, a publicly traded medical imaging software company (Nasdaq: VTAL) from 2008 until it was sold to Toshiba in 2011. Mr. Carrel attended Pennsylvia State University for his undergraduate degree and the Wharton School at the University of Pennsylvania for graduate school.
Mr. Jonathan Chen joined the Board on December 14, 2016. He has served as Senior Vice President of International Operations and Investor Relations of MicroPort Scientific since July, 2012 and the Chairperson of IEC since September, 2015. Mr. Chen's primary responsibilities include growing the company's International business in markets outside of China, primarily in the markets of the U.S, Europe and South America. Mr. Chen has over 17 years of experience in the medical device industry. Prior to joining the Company, Mr. Chen worked for Angiotech Pharmaceuticals, Inc. for 6 years, where he was Senior Vice President of Business Development. He led the management team to build a $300 million medical products business through various acquisitions and licensing transactions. Prior to joining Angiotech, Mr. Chen was a life sciences investment banker for Credit Suisse and Alex. Brown & Sons. He helped his clients raise in excess of $2 billion in equity and debt capital and advised on over $3 billion in Mergers & Acquisitions transactions. Mr. Chen has a Bachelor of Arts degree in Economics and a Bachelor of Sciences degree with honors in Biological Sciences from Stanford University.
Mr. HongBin Sun joined the Board on December 14, 2016. He serves as the Chief Financial Officer of MicroPort Scientific, the Co-Chairperson of CEC and a member of IEC. Mr. Sun is currently holding the executive directorship in Shanghai MicroPort Orthopedics Co., Ltd., a subsidiary of the MicroPort Scientific. Mr. Sun has over 16 years of finance experience. Mr. Sun was the Director and General Manager of Otsuka China from 2006 to July 2010. From 2004 to 2006, he served as a Financial Director of Otsuka China. From 1998 to 2003, Mr. Sun was an Assistant Manager of the Shanghai office of KPMG. Mr. Sun is a member of the Chinese Institute of Certified Public Accountants and is also a Chartered Financial Analyst. Mr. Sun received his bachelor's degree in Economics from Shanghai Jiao Tong University in China in 1998.